Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Other ETFs median (248 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 29 Dec 2021 – 20 Aug 2026, limited by Kotak Nifty Alpha 50 ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Kotak Nifty Alpha 50 ETF | Nifty 500 |
|---|---|---|
| 29 Dec 2021 | ₹100.00 | ₹100.00 |
| 19 May 2022 | ₹84.46 | ₹91.17 |
| 08 Oct 2022 | ₹86.25 | ₹101.17 |
| 26 Feb 2023 | ₹71.78 | ₹98.43 |
| 17 Jul 2023 | ₹92.46 | ₹113.51 |
| 05 Dec 2023 | ₹114.64 | ₹125.06 |
| 25 Apr 2024 | ₹140.51 | ₹140.40 |
| 13 Sep 2024 | ₹169.14 | ₹160.99 |
| 01 Feb 2025 | ₹139.11 | ₹145.19 |
| 22 Jun 2025 | ₹146.79 | ₹155.02 |
| 11 Nov 2025 | ₹144.68 | ₹159.34 |
| 01 Apr 2026 | ₹128.53 | ₹140.85 |
| 20 Aug 2026 | ₹157.64 | ₹158.19 |
| Metric | Kotak Mahindra NAV ₹53.77 Very High risk ★★★☆☆ | Category median Other ETFs · 248 funds |
|---|---|---|
| +9.13% | +3.65% | |
| +18.22% | +10.51% | |
| — | +9.28% | |
| — | +11.93% | |
| +10.31% | +10.38% | |
| +14.47% | — | |
| +18.49% | +14.30% | |
| — | +13.74% | |
| — | +12.83% | |
| Risk | ||
| 22.36% | 15.45% | |
| 0.52 | 0.28 | |
| 0.70 | 0.41 | |
| -33.46% | -20.59% | |
| Nifty 500 | — | |
| +4.29% | +0.80% | |
| 1.33 | 1.00 | |
| 147.4% | 102.1% | |
| 147.4% | 96.4% | |
| 0.57% | 0.32% | |
| ₹806.38Cr | ₹137.31Cr | |
| None | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| Abhishek Bisen | — | |
| 29 Dec 2021 | — | |
| 50 | — | |
| 34.7% | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.